|
Marijuana Abuse
|
0.010 |
Biomarker
|
disease |
BEFREE |
Prescribed treatment included 4 daily doses of 500 μg tetrahydrocannabinol each delivered from 16 mg cannabis flos per inhalation plus up to an additional four SOS (distress code for more doses of cannabis) doses.ResultDaily cannabis dose consumed during hospitalization with the Syqe Inhaler was 51 mg (20-96) versus 1,000 mg (660-3,300) consumed prehospitalization.
|
31196236 |
2020 |
|
Chronic Kidney Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Although all QUS parameters (SI, SOS and BUA) were associated with any or major fracture incidence in non-CKD and CKD patients, the magnitude of these associations was lower for any fracture and for BUA.
|
31676408 |
2020 |
|
Lipodystrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adipose tissue loss and lipodystrophy in xylosyltransferase II deficient mice.
|
30778123 |
2019 |
|
Liver diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
An exploratory multivariate model identified a past history of liver disease and thrombocytopenia before conditioning therapy as dominant risk factors for SOS after transplant.
|
30120894 |
2019 |
|
Thrombocytopenia
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
An exploratory multivariate model identified a past history of liver disease and thrombocytopenia before conditioning therapy as dominant risk factors for SOS after transplant.
|
30120894 |
2019 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Deletion of the Env cytoplasmic tail improved the efficiency with which the SOS Env supported virus infection in a reducing environment.
|
30944182 |
2019 |
|
Aneurysm, Ruptured
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patterns of care for ruptured aneurysms of the middle cerebral artery: analysis of a Swiss national database (Swiss SOS).
|
31731273 |
2019 |
|
Desbuquois syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Biallelic variants in XYLT1 and XYLT2, encoding xylosyltransferases, are associated with Desbuquois dysplasia type 2 and spondylo-ocular syndrome, respectively.
|
31438591 |
2019 |
|
Drug-Induced Liver Disease
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that ADCs that do not target antigens present in the normal liver have a relatively low frequency of SOS, but a relatively high frequency of DILI.
|
30120894 |
2019 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results corroborate the AcrAB-TolC efflux pump and the SOS response proteins, RecA and RecC, as potential targets for ciprofloxacin helper drugs in treatment of human bacterial infections caused by <i>E. coli</i> strains with intermediate sensitivity to ciprofloxacin.
|
30013537 |
2018 |
|
Cerebral Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The Barrow Neurological Institute Grading Scale as a Predictor for Delayed Cerebral Ischemia and Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From a Nationwide Patient Registry (Swiss SOS).
|
29351673 |
2018 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Latent moderated structural equations demonstrated that the relationship between SOS-SC and depression is moderated by social support (Sample 2), further validating the SOS-SC.
|
29052030 |
2018 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Latent moderated structural equations demonstrated that the relationship between SOS-SC and depression is moderated by social support (Sample 2), further validating the SOS-SC.
|
29052030 |
2018 |
|
Hepatitis B
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Awareness campaigns and voluntary hepatitis B screening were organized in the twelve districts of Ouagadougou by the "SOS Hepatitis Burkina" association.
|
30081915 |
2018 |
|
Hyperbilirubinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Typical symptoms of VOD/SOS may include hyperbilirubinemia, painful hepatomegaly, weight gain, and ascites.
|
29945939 |
2018 |
|
Acute myocardial infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.
|
30383755 |
2018 |
|
Iron deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results showed that iron deficiency causes <i>C. crescentus</i> cells to suffer oxidative stress and to activate the SOS response, indicating an increase in DNA damage.
|
30210482 |
2018 |
|
Vascular calcification
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Qualitatively, most PDIP-SOS CMR images showed good-to-excellent confidence to detect vascular calcifications, with good-to-excellent inter-reader agreement (κ = 0.67 for ilio-femoral region, P < 0.001; κ = 0.80 for aorto-iliac region, P < 0.01).
|
30078377 |
2018 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Latent moderated structural equations demonstrated that the relationship between SOS-SC and depression is moderated by social support (Sample 2), further validating the SOS-SC.
|
29052030 |
2018 |
|
Ewings sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT).
|
29335623 |
2018 |
|
Venoocclusive disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation.
|
30076031 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we examined the antibacterial effect of Tat (47-58) peptide, a cell-penetrating peptide, derived from human immunodeficiency virus-1 by focusing on the glutathione and SOS response.
|
30393132 |
2018 |
|
Arthritis, Psoriatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This report includes 1,991 subjects who underwent bariatric surgery and 2,018 controls with obesity from the SOS study; none of them had psoriasis or PsA at baseline.
|
29178583 |
2017 |
|
Lichen disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SOS response in bacteria: Inhibitory activity of lichen secondary metabolites against Escherichia coli RecA protein.
|
28515022 |
2017 |
|
Mixed Salivary Gland Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
The relationship between proteoglycan inhibition via xylosyltransferase II silencing and the implantation of salivary pleomorphic adenoma.
|
27732748 |
2017 |